IDEAYA Expands Roche Tie-Up: Genentech to Test IDE892 With KRAS G12D Inhibitor in Pancreatic Cancer
IDYA sits 63% above its 52-week low of $23.23.
Summary
IDEAYA announced a clinical collaboration with Genentech (Roche Group) to evaluate its PRMT5 inhibitor IDE892 in combination with Genentech's KRAS G12D inhibitor GDC-7035 (RG6620) in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma. Genentech will sponsor the trial, with IDEAYA supplying IDE892. This expands the existing Roche relationship beyond the June 3 collaboration (which paired IDE892 with Roche's RG6505 in MTAP-deleted RAS-mutant PDAC). The new combination targets a patient population where MTAP deletions and KRAS G12D mutations co-occur in up to ~15% of PDAC cases, with no approved targeted therapies. IDEAYA retains commercial rights to IDE892. The company plans to initiate a separate Phase 1 cohort with RG6505 in 2H 2026. This adds a second KRAS-directed combination partner for IDE892, strengthening the pipeline narrative ahead of the darovasertib NDA submission expected in H2 2026.
At the time of this announcement, IDYA was trading at $37.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $23.23 to $40.58. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.